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Abstract
Introduction: The revised shared epitope (SE) concept in rheumatoid arthritis (RA) is based on the presence (S) or
absence (X) of the SE RAA amino acid motif at positions 72 to 74 of the third hypervariable region of the various
human leucocyte antigen (HLA)-DRB1 alleles. The purpose of this study was to investigate SE subtypes on the basis
of the American College of Rheumatology 1987 revised criteria for the classification of RA in a cohort of South
African RA patients (n = 143) and their association with clinical and circulating biomarkers of disease activity
(autoantibodies, acute phase reactants and cytokines).
Methods: Genomic DNA was analysed using high-resolution recombinant sequence-specific oligonucleotide PCR
typing of the HLA-DRB1 allele. Subtypes of the SE were classified according to the amino acids at positions 72 to
74 for the RAA sequence, and further sub-divided according to the amino acids at positions 70 and 71, which
either contribute to (S2, S3P), or negate (S1, S3D) RA susceptibility. Disease activity was assessed on the basis of (1)
Disease Activity Score in 28 joints using C-reactive protein (CRP), (2) rheumatoid factor (RF), (3) CRP and (4) serum
amyloid A by nephelometry, anticyclic citrullinated peptide antibodies (aCCP) by an immunofluorometric
procedure, and cytokines by multiplex bead array technology.
Results: Of the 143 RA patients, 81 (57%) were homozygous (SS) and 50 (35%) were heterozygous (SX) for the SE
alleles with significant overexpression of S2 and S3P (respective odds ratios (ORs) 5.3 and 5.8; P < 0.0001), and 12
(8%) were classified as no SE allele (XX). Both the SS and SX groups showed a strong association with aCCP
positivity (OR = 10.2 and P = 0.0010, OR = 9.2 and P = 0.0028, respectively) relative to the XX group. Clinical scores
and concentrations of the other biomarkers of disease activity (RF, CRP and T helper cell type 1 (Th1), Th2,
macrophage and fibroblast cytokines) were also generally higher in the SS group than in the SX and XX groups.
Conclusions: RA susceptibility alleles investigated according to revised criteria for the classification of RA were
significantly increased in South African RA patients and strongly associated with aCCP in particular as well as with
circulating cytokines and disease severity.
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Introduction
Rheumatoid arthritis (RA) is a debilitating autoimmune
disease that has no clearly defined aetiology, although
there is a definite genetic predisposition and associated
risk factors [1]. The shared epitope (SE) concept in rela-
tion to genetic predisposition was first described in 1986
and has evolved from the classic HLA-DRB1*01, HLA-
DRB1*04 and HLA-DRB1*10 associations [2-4] to the
identification of the RAA amino acid motif at positions
72 to 74 of the third hypervariable region of the differ-
ent human leucocyte antigen (HLA)-DRB1 chains as the
definitive SE [3-5]. This concept has been extended by
Gao et al. [6] to include the amino acid residues at posi-
tions 71 and 76 and, recently, to a new classification
which incorporates the modulatory activities of the
amino acids at positions 70 and 71 in addition to the
RAA motif at positions 72 to 74 [6-8].
Although the primary triggering autoantigens in RA
have not been described to date, it is noteworthy that
associations between the various HLA-DRB1 SE sub-
types with disease susceptibility and/or severity and the
presence of circulating anticitrullinated peptide antibo-
dies have been described [9-18]. In addition, HLA-DRB1
SE genotyping and measurement of anticyclic citrulli-
nated peptide antibodies (aCCP) and, to a lesser extent,
rheumatoid factor (RF) have the potential to predict
future development of RA [10,14,17,19-21]. Taken
together, these associations between HLA-DRB1 SE gen-
otype, aCCP and disease susceptibility and/or severity
appear to be compatible with the presentation of citrul-
linated autoantigens by HLA-DRB1 SE subtypes as an
immunopathogenic mechanism in RA.
While lacking diagnostic specificity, the measurement of
circulating cytokines and chemokines and acute phase
reactants, combined with the detection of aCCP and RF,
has the potential to predict the time until onset of clinical
disease [22,23] as well as disease severity [24-27]. Nonethe-
less, in relatively few studies have researchers undertaken a
composite analysis of SE genotyping and measurement of
circulating aCCP, cytokines, chemokines and acute phase
reactants as a strategy not only to identify interactions
between these alleles and biomarkers but also to establish
which combinations of these are most strongly associated
with disease severity. These issues were addressed in the
current study of a cohort of predominantly African patients
with RA of two years’ duration or less. To our knowledge,
this is the first study to measure the frequency of the var-
ious SE subtypes according to the du Montcel classification
system [7] in this patient population.
Materials and methods
Following approval by the Research Ethics Committees
of the Faculties of Health Sciences of the University of
Pretoria and University of the Witwatersrand, 143
patients who presented to the rheumatology clinics of
two tertiary hospitals in the Gauteng Province of South
Africa (Chris Hani Baragwanath Hospital, Soweto, and
Steve Biko Academic Hospital, Pretoria) were recruited
to participate in the study. Prior informed consent was
obtained from all participants, all of whom met the
1987 American College of Rheumatology criteria for RA
[28]. All of the patients were disease-modifying anti-
rheumatic drug (DMARD)-naïve and HIV-seronegative
and had RA symptoms of two years’ duration or less.
The Disease Activity Score in 28 joints (DAS28) on the
basis of CRP level (DAS28-CRP) was used to assess dis-
ease activity upon presentation [29,30]. “Erosive disease”
was defined as the presence of marginal joint erosions
on standard X-rays of the hands and feet. These clinical
assessments were performed by two experienced rheu-
matologists (BH and MA). Demographic data for this
cohort are shown in Table 1.
Autoantibodies and acute phase reactants
Venous blood (30 ml) was collected in commercial sam-
ple test tubes containing a gel separator. The blood
samples were kept at room temperature to clot and
then spun at 3,000 rpm for 10 minutes), followed by
collection of the serum, aliquoting and storage at -20°C
until needed for analysis.
RF (composite immunoglobulin M (IgM), IgG and
IgA), CRP and serum amyloid A (SAA) were assayed by
Table 1 Demographic, laboratory and clinical data for the
RA patient group (n = 143)
Parameters Data Median [IQR] Range
Age (years) 48 ± 12 48 [41 to 56] 20 to 75
Females, n (%) 118 (82.5%)
Blacks, n (%) 124 (86.7%)
DAS28-CRP 5.6 ± 1.3 5.7 [4.8 to 6.7] 2.3 to 8.7
Disease duration (months) 12 ± 7 10 [6 to 18] 0 to 25
Larsen radiographic scores 23 ± 14 19 [14 to 28] 1 to 66
RF (IU/ml) 490 ± 795 168 [38 to 595] 4 to 5,350
aCCP (U/ml) 669 ± 636 492 [85 to 1,099] 2 to 2,527
CRP (μg/L) 24 ± 32 14 [5 to 32] 0 to 198
SAA (μg/ml) 62 ± 123 14 [5 to 65] 1 to 882
aCCP = anticyclic citrullinated peptide antibodies; CRP = C-reactive protein;
DAS28 = Disease Activity Score in 28 joints; RF = rheumatoid factor; SAA =
serum amyloid A. Data are means ± SD, n (%), medians [25th to 75th IQR] or
raw data as indicated.
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Diagnostics, Deerfield, IL, USA). As per the manufac-
turer’s supplier controls, RF, CRP and SAA results were
considered positive when their individual concentrations
exceeded 11 IU/ml, 5 μg/ml and 6.8 μg/ml, respectively.
aCCP were measured using a second-generation immu-
nofluorometric procedure using the ImmunoCAP Pha-
d i a2 5 0a s s a ys y s t e mw i t hr e a g e n t sa n dc o n t r o l s
provided by the manufacturer (Phadia AB, Uppsala,
Sweden). A concentration greater than 10 U/ml was
deemed positive.
Serum cytokines, chemokines and growth factors
Serum cytokines, chemokines and growth factors were
measured using the Bio-Plex multiplex suspension array
system with xMAP technology (Bio-Rad Laboratories,
Hercules, CA, USA), which enables simultaneous detec-
tion and quantitation of multiple different analytes in a
single sample. The system uses an array of microspheres
in liquid suspension that are conjugated with a mAb
specific for a target protein. A wide range of standards
(0.38 to 91,756.00 pg/ml) was used to enable quantita-
tion of the individual cytokines by using a Bio-Plex
array reader (Bio-Rad Laboratories) with a dual laser
detector and real-time digital signal processing. The fol-
lowing analytes were measured: IL-1b, IL-1Ra, IL-2, IL-
4, IL-6, IL-7, IL-8, IL-10, IL-12, IL-17, IFN-g,T N F ,
granulocyte colony-stimulating factor (G-CSF), granulo-
cyte macrophage colony-stimulating factor (GM-CSF),
chemokine (C-C motif) ligand 2 (CCL2), CCL4 and vas-
cular endothelial growth factor (VEGF). The upper lim-
its of normal for these analytes were calculated as the
mean +2 SD for 10 healthy control subjects (five female
and five male, average age 44.4 ± 15.0 years, age range
26 to 65 years).
Typing of human leucocyte antigen-DRB1 alleles
Genomic DNA was obtained by using the Maxwell 16
System with the Maxwell 16 Blood DNA Purification
Kit (Promega, Madison, WI, USA) to extract DNA from
whole blood, which was collected in ethylenediaminete-
traacetic acid (EDTA) sample tubes. The patients’ HLA-
D R B 1a l l e l e sw e r ed e t e r m i n e db yu s i n gaD N A - b a s e d
high-resolution typing method, the LABType HD Class
II DRB1 Typing Test (One Lambda Inc, Canoga Park,
CA, USA), with reverse sequence-specific oligonucleo-
tide probes and Luminex technology. The target DNA
(HLA-DRB1 gene) was amplified by PCR using group-
specific primers biotinylated for detection with streptavi-
din R-phycoerythrin conjugate. The PCR product was
then denatured and hybridised to complementary DNA
probes conjugated to fluorophores. Bound DNA was
detected on the Luminex system, and software (HLA
Fusion&#8482 Software Version 2.0, One Lambda,
Inc.,21001 Kittridge Street, Canoga Park, CA, USA)was
used to map the reaction patterns to those associated
with published HLA gene sequences and assign the
represented HLA-DRB1 alleles. HLA alleles were
assigned according to the RAA amino acid sequence at
positions 72-74 as SE (S) and non-SE (X), and the S
group was further subdivided according to amino acid
groups at positions 70 and 71 as described by du Mon-
tcel et al. [7] (see Table 2). The International Immuno-
genetics Information System database [31,32] and the
Allele*Frequencies in Worldwide Populations Net Data-
base [33] were used to establish regional and ethnicity-
matched HLA-DRB1 frequencies in sub-Saharan Africa.
The non-SE patients with the no SE allele (XX) geno-
type (n = 12) were used as controls in the calculation of
contingency tables.
Statistical methods
Descriptive and inferential statistics techniques were
used in the analyses. Tests for association of contin-
gency tables were performed using either the two-tailed
Fisher’s exact test or the c
2 test with the Yates correc-
tion. One-way analysis of variance (ANOVA) was per-
formed using the Kruskal-Wallis test for nonparametric
data for more than two groups, or the Mann-Whitney U
test when two groups were compared. Logistic regres-
sion was used for binary outcome variables, and the OR
and corresponding 95% confidence interval were
reported. P < 0.05 was considered statistically significant.
T h ea n a l y s e sw e r ed o n eu s i n gS t a t as o f t w a r e( S t a t a
Corp, College Station, TX, USA).
Results
Human leucocyte antigen-DRB1 incidence
All of the “classical” RA-associated HLA-DRB1*01,
HLA-DRB1*04 and HLA-DRB1*10 alleles showed statis-
tically significant ORs, with HLA-DRB1*04 the most
prominent (Table 3), underscoring the significance of
the HLA-DRB1 SE previously reported in the African
population [34-38]. The HLA-DRB1 alleles were cate-
gorized according to the new classification as being
homozygous for the SE allele (SS), heterozygous for the
SE allele (SX) or XX. The majority (92%) of the patients
had at least one allele associated with the amino acid
motif. More than half (57%) of the patients typed were
homozygous (SS), 35% were heterozygous (SX) and only
8% had no associated HLA-DRB1 allele (XX). The SS,
SX and XX allele distribution among the African sub-
group of the cohort (n = 124) was 58% (n = 72), 35% (n
=4 3 )a n d7 %( n = 9), respectively. The other South
African population groups (Caucasian, Asian and mixed
ancestry) were not meaningfully represented, however.
Classification of RA-associated HLA-DRB1 alleles
according to the du Montcel et al. classification system
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allele frequencies than those found in the general sub-
Saharan population [32,33]. S3D and the non-epitope-
associated alleles (X) were not significantly different in
the RA groups compared to the general sub-Saharan
population. As shown in Table 4, S1 was significantly
undertransmitted in our population.
Relationship of shared epitope classification and
autoantibodies
Analysis (by one-way ANOVA and Mann-Whitney U
test) of the median values of autoantibodies revealed
that they were generally higher in the SS group than in
the SX group. Significant associations were noted for
aCCP (SS vs SX vs XX; P = 0.0298) and for RF (SS vs
XX, P = 0.0129; SX vs XX, P = 0.0273).
As X alleles have been shown to be undertransmitted
in the RA cohort (that is, noncarriers of risk alleles) (see
Table 4), they were used as the control group within the
RA cohort to determine the possible associations of the
HLA-DRB1 genotype with RA-associated autoantibodies
by comparing the total positive and negative results for
the RA-associated antibodies (RF and aCCP) in the risk
groups with those for the control group (XX). As shown
in Table 5, both RF and aCCP seropositivity were signif-
icantly higher in both the SS and SX groups of the total
cohort in comparison with the XX control group. The
data are as follows: RF (SS group vs XX control group:
OR = 7.0, P = 0.0059, and SX group vs XX control
group: OR = 6.3, P = 0.0126) and aCCP (SS group vs
XX control group: OR = 10.2, P = 0.0010, and SX group
vs XX control group: OR = 9.2, P = 0.0028).
The SS and SX groups of the African patients showed
a statistically significant predisposition to aCCP seropo-
s i t i v i t yc o m p a r e dw i t ht h eX Xg r o u p( S Sg r o u pv sX X
control group: OR = 7.01, P = 0.0121; SX group vs XX
control group: OR = 6.4, P = 0.0223), and RF was also
more prevalent in the SS and SX groups compared to
the XX control group, although the difference was not
significant (Table 5). Stratifying the patients according
to du Montcel et al.’s allele classification [7] as SS, SX
or XX therefore seems to strengthen the genetic associa-
tion with the presence of aCCP, an observation which is
in agreement with the findings of Huizinga et al.[ 1 4 ]
and Klareskog et al. [39].
Further analysis was undertaken to probe the associa-
tions with the amino acids at positions 70 and 71 (S1,
S2, S3D and S3P) with aCCP seropositivity by compar-
ing noncarriers with the carrier allele groups. As shown
in Table 6, this analysis revealed significantly higher
O R si nt h ec a s eo ft h eS 2a n dS 3 Pa l l e l eg r o u p sa n d
weak, albeit significant, associations with the S1, S3D
and X allele groups. RF seropositivity was weakly asso-
ciated with all allele groups.
The association between SE genotype and aCCP or RF
seropositivity was further probed by categorising
patients into high-risk or low-risk allele groups accord-
ing to the du Montcel classification system [7] with the
Table 2 Shared epitope classification according to amino acid sequence at positions 70-74
Allele classification Amino acid sequence positions 70 to 74 HLA-DRB1 alleles
S1 D-E-RAA *01:03, *04:02, *11:02-:03, *13:01-:02, *13:04, *13:36, *13:40
Q-A-RAA *15
S2 Q-K-RAA *04:01, *04:09, *04:13, *04:35, *04:66
D-K-RAA *13:03
S3D D-R-RAA *11:01, *11:04, *11:27, *12, *13:05-:06, *13:25, *14:22, *16
S3P Q-R-RAA *01:01-:02, *04:04-:05, *04:08, *04:10
R-R-RAA *10:01
X Q-K-RGR *03
Q-R-RAE *04:03, *04:07, *04:11
D-R-RGQ *07
D-R-RAL *08
R-R-RAE *09:01, *14:01, *14:04
HLA = human leucocyte antigen. Data in right column from Gao et al. [6].
Table 3 Human leucocyte antigen-DRB1 rheumatoid arthritis-associated alleles, odds ratios and confidence intervals in
the rheumatoid arthritis patient cohort
Risk allele RA patients, n (%) (n = 143) Controls*, n (%) (n = 1,104) OR (95% CI) P value
HLA-DRB1*01 26 (18.2) 93 (8.4) 2.4 (1.5 to 3.9) 0.0007
HLA-DRB1*04 61 (42.7) 41 (3.7) 19.3 (12.2 to 30.4) <0.0001
HLA-DRB1*10 10 (7.0) 36 (3.3) 2.2 (1.0 to 4.6) 0.0338
HLA = human leucocyte antigen; OR = odds ratio; RA = rheumatoid arthritis. *Data from Robinson and colleagues [31,32].
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type groups were (1) S1, consisting of genotypes S1/S1
+ S1/X; (2) S3D, consisting of S3D/S3D + S3D/X; and
(3) S1/S3D, consisting of S1/S1 + S1/X + S3D/S3D +
S3D/X + S1/S3D. The high-risk genotype groups were
(1) S2, consisting of genotypes S2/S2 + S2/X; (2) S3P,
consisting of S3P/S3P + S3P/X; and (3) S2/S3P, consist-
ing of S2/S2 + S2/X + S3P/S3P + S3P/X + S2/S3P. As
shown in Table 7, these comparisons revealed a highly
significant risk associated with the S2/S3P, S3P and S1/
S 3 Dg r o u p sa n d ,t oal e s s e re x t e n t ,S 1a n dS 3 Da s
described in previous studies [21,40]. No predisposing
effect associated with RF seropositivity was identified,
which confirms that the SE alleles are primarily asso-
ciated with aCCP.
Relationship of shared epitope with other circulating
biomarkers and clinical markers of disease activity
Analysis (one-way ANOVA and Mann-Whitney U test)
of the median values of the other circulating biomarkers
and clinical markers of disease activity revealed signifi-
cant associations with CRP (SS vs SX vs XX: P =
0.0041; SS vs SX: P = 0.0018), SAA (SS vs SX vs XX: P
= 0.0018; SS vs SX: P = 0.0005), TNF (SS vs SX vs XX:
P = 0.0295), IL-1Ra (SS vs XX: P = 0.0311) and DAS28
(SS vs SX vs XX: P = 0.0324; SS vs XX: P = 0.0103; SX
vs XX: P = 0.0210). These trends were also noted with
regard to most of the other cytokines, although they
were not statistically significant (IL-1b, IL-2, IL-4, IL-6,
IL-8, IL-12, CCL4, G-CSF, GM-GSF and IFN-g).
Statistical comparison of the S1, S2, S3D and S3P
groups did not reveal any significant differences, but in
general the highest means for acute phase reactants,
proinflammatory or anti-inflammatory cytokines, che-
mokines and VEGF were located predominantly in the
SS-associated groups (data not shown).
Discussion
Relatively few studies have been undertaken to evaluate
the occurrence of RA-associated HLA-DRB1 alleles in
southern African people with RA. The results of the
current study, on the basis of high-resolution typing
procedures in combination with the du Montcel HLA-
DRB1 SE classification system [7], reveal that the inci-
dence of RA risk-associated alleles in a population of
predominantly black South African females with RA is
comparable to or higher than those reported in Eur-
opean and Japanese populations [19-21] and somewhat
higher than those reported in the relatively few studies
undertaken in African Americans, which range from
25% to 40% [35-37]. Our data are in agreement with
those of an earlier study where low-resolution PCR typ-
ing procedures were used, in which HLA-DRB1*04 con-
ferred the most significant risk of RA in a cohort of
black South African RA patients [38]. According to the
du Montcel classification system [7], the highest risk of
RA is associated with the S2 and S3P alleles. Recently,
Barnetche et al. [19] reported an association between
RA susceptibility and HLA-DRB1 alleles (categorized
according to the du Montcel classification system [7]) in
a combined analysis of worldwide samples (1,210 cases
of RA), which included 23 San people of southern Afri-
can origin. Although the number of cases was small,
52.2% of the patients were found to be carriers of the S2
RA susceptibility allele compared to 26% in the control
group (OR = 3.05) [19]. In addition, in agreement with
Table 4 Comparison of allele carrier frequencies in RA cases and controls in accordance with the du Montcel
classification
Allele RA patients, n (%) (n = 143) Controls
*, n (%) (n = 1,104) Χ
2 test OR (95% CI) P value
S1 55 (39) 853 (77) 40.3 0.4 (0.3 to 0.5) <0.0001
S2 28 (20) 110 (10) 10.3 2.0 (1.3 to 3.2) 0.0013
S3D 38 (27) 361 (33) 0.1 0.9 (0.6 to 1.3) 0.7060
S3P 61 (43) 313 (28) 9.6 1.6 (1.2 to 2.2) 0.0019
X 64 (45) 616 (56) 3.6 0.8 (0.6 to 1.0) 0.0571
RA = rheumatoid arthritis. du Montcel classification is from du Montcel et al. [7]. *Data from Robinson and colleagues [31,32].
Table 5 Relationship between human leucocyte antigen-DRB1 shared epitope homozygosity or heterozygosity and
risk of anticyclic citrullinated peptide antibody or rheumatoid factor seropositivity
Total cohort (n = 143) Blacks (n = 124)
SS (n = 80) SX (n = 52) SS (n = 72) SX (n = 43)
OR (95% CI) P value OR (95% CI) P value OR (95% CI) P value OR (95% CI) P value
RF 7.0 (1.8 to 26.6) 0.0059 6.3 (1.5 to 25.7) 0.0126 4.5 (1.0 to 19.5) 0.0537 4.1 (0.9 to 19.3) 0.0813
aCCP 10.2 (2.6 to 40.3) 0.0010 9.2 (2.2 to 38.9) 0.0028 7.1 (1.6 to 30.4) 0.0121 6.4 (1.4 to 30.1) 0.0223
aCCP = anticyclic citrullinated peptide antibodies; HLA = human leucocyte antigen; RF = rheumatoid factor; SE = shared epitope; SS = homozygous for shared
epitope allele; SX = heterozygous for shared epitope allele.
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[19,40], we observed highly significant associations of SS
and SX with seropositivity for aCCP but not RF [21,40].
We have previously reported that isolated measurement
of aCCP is no more accurate than RF in the serodiagno-
sis of RA [41]. However, when used in combination
with SE genotyping, measurement of aCCP appears to
distinguish a subset of patients who may differ with
respect to response to therapy and outcome.
These observations appear to support the relationship
between HLA-DRB1 SE subtypes, presentation of citrul-
linated epitopes and development of RA [42]. This con-
tention is underscored by the broad associations of
circulating cytokines with the du Montcel classification
system risk phenotype [7]. SS is most strongly associated
with T-helper cell 1 (GM-CSF, TNF, IFN-g and IL-2),
Th2 (IL-4 and IL-6) and macrophage (IL-1b,I L - 6 ,I L - 8 ,
IL-12, TNF and VEGF) cytokines, as well as with IL-
1Ra. We and others have previously reported that RA is
associated with a generalised increase in circulating
proinflammatory and anti-inflammatory cytokines and
chemokines, which might be compatible with Th1,
macrophage and fibroblast activation and a counterregu-
latory role of Th2 cells [22,23,43].
Our findings are somewhat at variance with those
recently reported by Singwe-Ngandeu et al. [44] in a
relatively small group of Cameroonian RA patients (n =
56). Thirty percent of the RA patients in their study
were either SS or SX compared to 10% in patients with
other inflammatory rheumatic diseases and 14% in
healthy controls. However, no significant associations
between SE positivity (SS or SX) and aCCP or RF were
detected. Several possible reasons might explain the dif-
ferences between their study and our present study.
Notwithstanding the relatively small number of patients,
these differences include the number of alleles typed (21
in Singwe-Ngandeu et al. vs 43 in our present study)
and, most importantly, the effects of chemotherapy.
Whereas the patients in our study were corticosteroid-
and DMARD-naïve at the time of presentation, the
patients in the Singwe-Ngandeu et al. study were receiv-
ing prednisone (91%), methotrexate (77%), sulfasalazine
(12%), azathioprine (5%), leflunomide (5%) and D-peni-
cillamine (2%). Although this difference may explain the
absence of associations of SE alleles with aCCP and RF,
it is unlikely to explain the differences in frequencies of
SE alleles detected in the two studies. Notwithstanding
the larger number of alleles typed in the current study,
it is also possible that our patients represent those at
the extreme end of the severe disease spectrum. In the
health care setting of the developing world, the presen-
tation of patients to specialised RA clinics, of which
there are few, is likely to be delayed, and our study
cohort may therefore reflect a selection bias of patients
seen in a tertiary setting.
Conclusions
The results of the current study demonstrate an
increased frequency of high-risk SE alleles in a predomi-
nantly black South African population with RA. We
have also shown a clear association of high-risk SE
alleles with aCCP in particular, to a lesser extent with
RF, with circulating cytokines and chemokines and pos-
sibly with disease severity.
Abbreviations
aCCP: anticyclic citrullinated peptide antibodies; CRP: C-reactive protein;
DAS28: Disease Activity Score in 28 joints; DMARD: disease-modifying
antirheumatic drug; HLA: human leucocyte antigen; IFN: interferon; IL:
interleukin; mAb = monoclonal antibody; PCR: polymerase chain reaction;
Table 6 Association between anticyclic citrullinated
peptide antibody and rheumatoid factor with shared
epitope alleles according to the du Montcel classification
aCCP RF
Allele OR (95% CI) P value OR (95% CI) P
value
S1 allele (n = 55) 2.9 (0.7 to 12.4) 0.2054 4.5 (1.2 to
16.9)
*0.0291
S2 allele (n = 28) 12.0 (2.4 to
59.5)
0.0019** 8.3 (1.6 to
43.3)
*0.0122
S3D allele (n =
38)
7.5 (1.8 to 31.4) 0.0100* 5.3 (1.3 to
22.7)
*0.0246
S3P allele (n = 61) 13.3 (3.2 to
54.4)
0.0003*** 4.5 (1.2 to
16.8)
*0.0264
X allele (n = 64) 4.7 (1.2 to 17.6) 0.0213* 2.7 (0.8 to 9.8) 0.1678
aCCP = anticyclic citrullinated peptide antibodies; RF = rheumatoid factor. du
Montcel classification is from du Montcel et al. [7]. OR (95% CI) and P values
were calculated using Fisher’s exact test to compare with SE noncarrier
rheumatoid arthritis patients (n = 12). *P < 0.05. **P ≤ 0.001 and ***P ≤ 0.0003
values are highly significant.
Table 7 Predisposing effect of shared epitope genotypes
on anticyclic citrullinated peptide antibody and
rheumatoid factor seropositivity
aCCP RF
SE groups OR (95% CI) P value OR (95% CI) P value
S1 (n = 24) 2.4 (1.1 to 5.4) 0.0113* 1.6 (0.9 to 2.9) 0.1245
S3D (n = 17) 2.3 (1.0 to 5.4) 0.0287* 1.7 (0.9 to 3.0) 0.1059
S1/S3D (n = 50) 2.3 (1.0 to 5.3) 0.0049** 1.6 (0.9 to 2.9) 0.0611
S2 (n = 11) 2.2 (0.9 to 5.2) 0.0995 1.6 (0.9 to 3.1) 0.1930
S3P (n = 28) 2.5 (1.1 to 5.6) 0.0075** 1.6 (0.9 to 3.0) 0.0563
S2/S3P (n = 47) 2.4 (1.1 to 5.5) 0.0025** 1.6 (0.9 to 2.8) 0.0687
aCCP = anticyclic citrullinated peptide antibodies; RF = rheumatoid factor; SE
= shared epitope. OR (95% CI) and P values were calculated using Fisher’s
exact test to compare rheumatoid arthritis patients with RA patients with the
X/X genotype (n = 12). *P < 0.05. **P ≤ 0.008 values are highly significant.
Groups S1, S3D, S2 and S3P consisted of the pooled homozygotes (SS) and
heterozygotes (SX) for each group. Group S1/S3D consisted of S1/S1, S1/X,
S3D/S3D, S3D/X and S1/S3D. Group S2/S3P consisted of S2/S2, S2/X, S3P/S3P,
S3P/X and S2/S3P.
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homozygous for shared epitope allele; SX: heterozygous for shared epitope
allele; Th: T helper cell; TNF: tumour necrosis factor; XX: no shared epitope
allele.
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